Transparency is a critical part of our ongoing collaboration with key stakeholders, helping to build a community of trust and respect with healthcare professionals, patients, industry peers, stockholders and the public.

Biogen is committed to transparency and disclosure of issues that are material to the business and of interest to our stakeholders.


ESG Materiality Assessment Process

As part of the review of our global Corporate responsibility strategy, between 2019 and 2020, we conducted a materiality assessment, engaging a broad range of stakeholders, adopting a new approach to questions and a deeper analysis to identify and prioritize the environmental, social, and governance (ESG) issues at the intersection of stakeholder and company concern.

Read the detailed results of our materiality assessment in our Reporting section.

Taskforce on Climate-Related Financial Disclosure Statement

Biogen supports the Taskforce on Climate-related Financial Disclosure (TCFD). Through our 2020 TCFD statement, we provide our first disclosure aligned with TCFD recommendations. 

Read our TCFD Statement.


Safe Harbor

Our 2020 Year in Review contains forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Read our safe harbor statements.


Additional Resources:

Report Archive


Quick Links


Read the Data and Indices